Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?
Identifieur interne : 000381 ( Main/Curation ); précédent : 000380; suivant : 000382Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?
Auteurs : Carl E. Clarke [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Caroline Rick [Royaume-Uni] ; Keith Wheatley [Royaume-Uni] ; Richard Gray [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-06.
English descriptors
Abstract
Background:: Evidence from clinical trials with monoamine oxidase type B inhibitors (TEMPO, ADAGIO and DATATOP) and levodopa (ELLDOPA) suggests that Parkinson's disease patients may benefit from treatment being commenced immediately on diagnosis rather than waiting for functional disability to develop, as is traditional clinical practice. Methods:: We performed a narrative literature review and meta‐analysis of delayed‐start design trials in Parkinson's disease. Results:: There was inconsistency in the results of the two rasagiline delayed‐start design trials, with early treatment with a 2 mg dose significantly superior in the TEMPO trial, but the 1 mg dose significantly better in the ADAGIO trial, making interpretation difficult. Further, the benefits of immediate treatment were small in terms of total unified Parkinson's disease rating scale scores, with a mean difference of 0.91 units (95% confidence interval 0.01, 1.80; P=0.05) in a meta‐analysis of the TEMPO and ADAGIO delayed‐start design trials. Such small differences are unlikely to be of clinical relevance. There is also little information on whether immediate treatment has a beneficial effect on patient quality of life with an acceptable adverse reaction profile, and we have no data on whether imediate treatment is cost‐effective. Discussion:: Based on the evidence available, changing clinical practice to immediate therapy on diagnosis is not warranted and further trials are needed. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23519
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000441
Links to Exploration step
ISTEX:FADC67D06D13B4945AFC1F50983F3B2BB4842AF2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?</title>
<author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, City Hospital, Sandwell and West Birmingham NHS Trust, Dudley Road, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neurology, City Hospital, Sandwell and West Birmingham NHS Trust, Dudley Road, Birmingham</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rick, Caroline" sort="Rick, Caroline" uniqKey="Rick C" first="Caroline" last="Rick">Caroline Rick</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wheatley, Keith" sort="Wheatley, Keith" uniqKey="Wheatley K" first="Keith" last="Wheatley">Keith Wheatley</name>
<affiliation wicri:level="1"><mods:affiliation>Cancer Research UK Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cancer Research UK Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gray, Richard" sort="Gray, Richard" uniqKey="Gray R" first="Richard" last="Gray">Richard Gray</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:FADC67D06D13B4945AFC1F50983F3B2BB4842AF2</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23519</idno>
<idno type="url">https://api.istex.fr/document/FADC67D06D13B4945AFC1F50983F3B2BB4842AF2/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">000441</idno>
<idno type="wicri:Area/Main/Curation">000381</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?</title>
<author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, City Hospital, Sandwell and West Birmingham NHS Trust, Dudley Road, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neurology, City Hospital, Sandwell and West Birmingham NHS Trust, Dudley Road, Birmingham</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rick, Caroline" sort="Rick, Caroline" uniqKey="Rick C" first="Caroline" last="Rick">Caroline Rick</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wheatley, Keith" sort="Wheatley, Keith" uniqKey="Wheatley K" first="Keith" last="Wheatley">Keith Wheatley</name>
<affiliation wicri:level="1"><mods:affiliation>Cancer Research UK Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cancer Research UK Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gray, Richard" sort="Gray, Richard" uniqKey="Gray R" first="Richard" last="Gray">Richard Gray</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-06">2011-06</date>
<biblScope unit="volume">26</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="1187">1187</biblScope>
<biblScope unit="page" to="1193">1193</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">FADC67D06D13B4945AFC1F50983F3B2BB4842AF2</idno>
<idno type="DOI">10.1002/mds.23519</idno>
<idno type="ArticleID">MDS23519</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>health economics</term>
<term>quality of life</term>
<term>treatment</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background:: Evidence from clinical trials with monoamine oxidase type B inhibitors (TEMPO, ADAGIO and DATATOP) and levodopa (ELLDOPA) suggests that Parkinson's disease patients may benefit from treatment being commenced immediately on diagnosis rather than waiting for functional disability to develop, as is traditional clinical practice. Methods:: We performed a narrative literature review and meta‐analysis of delayed‐start design trials in Parkinson's disease. Results:: There was inconsistency in the results of the two rasagiline delayed‐start design trials, with early treatment with a 2 mg dose significantly superior in the TEMPO trial, but the 1 mg dose significantly better in the ADAGIO trial, making interpretation difficult. Further, the benefits of immediate treatment were small in terms of total unified Parkinson's disease rating scale scores, with a mean difference of 0.91 units (95% confidence interval 0.01, 1.80; P=0.05) in a meta‐analysis of the TEMPO and ADAGIO delayed‐start design trials. Such small differences are unlikely to be of clinical relevance. There is also little information on whether immediate treatment has a beneficial effect on patient quality of life with an acceptable adverse reaction profile, and we have no data on whether imediate treatment is cost‐effective. Discussion:: Based on the evidence available, changing clinical practice to immediate therapy on diagnosis is not warranted and further trials are needed. © 2011 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000381 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000381 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:FADC67D06D13B4945AFC1F50983F3B2BB4842AF2 |texte= Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? }}
This area was generated with Dilib version V0.6.23. |